Piper Sandler Companies (PIPR)
| Bid | 319.33 |
| Market Cap | 5.65B |
| Revenue (ttm) | 1.58B |
| Net Income (ttm) | 210.94M |
| EPS (ttm) | 11.88 |
| PE Ratio (ttm) | 26.91 |
| Forward PE | 17.87 |
| Analyst | Hold |
| Ask | 320.24 |
| Volume | 32,137 |
| Avg. Volume (20D) | 155,450 |
| Open | 321.76 |
| Previous Close | 322.06 |
| Day's Range | 305.78 - 322.56 |
| 52-Week Range | 202.91 - 351.80 |
| Beta | 1.49 |
About PIPR
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for PIPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago · https://thefly.com
Ollie's Bargain Outlet price target raised to $150 from $123 at Piper SandlerPiper Sandler raised the firm's price target on Ollie's Bargain Outlet to $150 from $123 and keeps an Overweight rating on the shares. Fundamentals across the discount retailer space have improved as ...
2 days ago · https://thefly.com
Dollar Tree price target raised to $112 from $93 at Piper SandlerPiper Sandler analyst Peter Keith raised the firm's price target on Dollar Tree to $112 from $93 and keeps a Neutral rating on the shares. Fundamentals across the discount retailer space have improved...
2 days ago · https://thefly.com
Piper starts Summit Therapeutics with Neutral on high expectationsPiper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target. The firm believes investor expectations for ivonescimab are too hi...
2 days ago · https://thefly.com
Ormat Technologies price target raised to $90 from $78 at Piper SandlerPiper Sandler raised the firm's price target on Ormat Technologies to $90 from $78 and keeps a Neutral rating on the shares. Shares are up 33% year to date as the improving regulatory environment and ...
2 days ago · https://thefly.com
Piper starts Janux Therapeutics with an Overweight on 'best-in-class' potentialAs previously reported, Piper Sandler initiated coverage of Janux Therapeutics with an Overweight rating and $42 price target. While noting that investor sentiment has waned over the course of 2025 fo...
2 days ago · https://thefly.com
Piper starts Revolution Medicines at Overweight on daraxonrasib potentialPiper Sandler analyst Kelsey Goodwin last night initiated coverage of Revolution Medicines with an Overweight rating and $75 price target. The firm believes the stock's value will be driven by confide...
2 days ago · https://thefly.com
Day One Biopharmaceuticals initiated with an Overweight at Piper SandlerPiper Sandler initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $25 price target. Piper thinks the stock move following the first two 2025 earnings reports is overdone and...
